• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

OHSU Cancer Institute to Use Sequenom's MassARRAY Technology for Cancer Research

Posted on: Monday, 9 June 2008, 06:00 CDT

Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced that Portland, Ore.-based Oregon Health & Science University (OHSU) Cancer Institute has purchased a MassARRAY(R) system for use in the discovery, development and testing of biomarker panels for rapid classification and characterization of cancer. The OHSU Cancer Institute is recognized worldwide for its cancer research.

"This placement at the prestigious OHSU Cancer Institute is a tremendous validation of MassARRAY technology's ability to advance the development of multiple biomarker sets or panels, allowing for the precise classification of tumors. This information could eventually guide rational cancer therapy and improve patient care," said Michael Monko, Sequenom Senior Vice President, Sales & Marketing. "Evidence of the MassARRAY's superior sensitivity and accuracy in characterizing heterogeneous tumors has been demonstrated in several studies recently published in peer-reviewed scientific journals."

"In cancer classification, we want to understand the underlying molecular mechanisms so that we can inform patients about their potential outcome and devise strategies for therapeutic intervention," said Dr. Brian Druker, Director of the OHSU Cancer Institute. "Specifically, we want to know as much about tumors as quickly and economically as possible and the MassARRAY system will significantly advance our ability to accomplish this."

About Sequenom

Sequenom is committed to providing the best genetic analysis products for research and the molecular diagnostic markets. The Company makes available superior solutions for genomic science in biomedical research, livestock and agricultural applications and molecular medicine, as well as for various diagnostic markets, including noninvasive prenatal testing, oncology and infectious diseases. Sequenom's proprietary MassARRAY system delivers reliable and specific data from complex biological samples and from genetic target materials available only in trace amounts.

Sequenom(R) and MassARRAY(R) are trademarks of Sequenom, Inc.

About the OHSU Cancer Institute

The OHSU Cancer Institute is a National Cancer Institute-designated cancer center and the only such facility between Sacramento and Seattle. It comprises over 120 clinical researchers, basic scientists and population scientists who work together to translate scientific discoveries into longer and better lives for cancer patients. It is most widely known for its translational research with its contribution to the development of molecularly targeted therapies, including imatinib (Gleevec).

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding OHSU's use of the MassARRAY system and the utility of and impact of information generated by the MassARRAY system on cancer therapy, patient care, and knowledge about tumors, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with demand for and market acceptance of Sequenom's products, services, and technologies, new technology and product development and commercialization, reliance upon the collaborative efforts of other parties, research and development progress, competition, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Source: Business Wire

More News in this Category